(Q56995052)

English

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

scientific article published on 01 October 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

C G Roehrborn

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Bergner

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

T Gray

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Gittelman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

T Shown

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Melman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R B Bracken

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R deVere White

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Taylor

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Waldstreicher

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

0 references

publication date

1 October 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

54

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

662-669

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

randomized experiment

0 references

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900232-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)00232-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10510925%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56995052&oldid=2171791890"